Page last updated: 2024-12-10
senkirkine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
senkirkine: macrocyclic secopyrrolizidine alkaloid from Senecio; structure given in first source; RN given refers to senkirkine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5281752 |
| CHEMBL ID | 470059 |
| CHEBI ID | 9111 |
| MeSH ID | M0053772 |
Synonyms (34)
| Synonym |
|---|
| renardin |
| senkarkane |
| senkirkin |
| senkirkine (neutral) |
| nsc-89945 |
| renardine |
| (1r,4z,6r,7r,11z)-4-ethylidene-7-hydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione |
| renardine (neutral) (van) |
| 4,8-secosenecionan-8,11,16-trione, 12-hydroxy-4-methyl- |
| hsdb 3536 |
| ccris 557 |
| senkirkine (neutral) (van) |
| 12-hydroxy-4-methyl-4,8-secosenecionan-8,11,16-trione |
| trans-15-ethylidene-12-beta-hydroxy-4,12-alpha,13-beta-trimethyl 8-oxo-4,8 secosenec-1-enine |
| 2,12-dihydroxy-4-methyl-11,16-dioxosenecionanium |
| senkirkine |
| CHEMBL470059 , |
| chebi:9111 , |
| AC1NQZ0B , |
| x65p7v4lvj , |
| unii-x65p7v4lvj |
| 2,9-dioxa-14-azabicyclo(9.5.1)heptadec-11-ene-3,8,17-trione, 4-ethylidene-7-hydroxy-6,7,14-trimethyl-, (1r,4z,6r,7r)- |
| senkirkine [iarc] |
| (1r,4z,6r,7r)-4-ethylidene-7-hydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo(9.5.1)heptadec-11-ene-3,8,17-trione |
| DTXSID4021266 , |
| senkirkine, analytical standard |
| mfcd01684247 |
| Q27108274 |
| HY-122509 |
| CS-0085930 |
| trans-15-ethylidene-12-beta-hydroxy-4,12-alpha,13-beta-trimethyl-8-oxp-4,8-secosenec-1-enine |
| dtxcid701266 |
| senkirkine (iarc) |
| senkirkine 100 microg/ml in water |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " In this study the content of the alkaloids senecionine (SCO), senkirkin (SKK) and seneciphyllin (SCP) and their toxic effects in cattle were studied." | ( Interplant alkaloid variation and Senecio vernalis toxicity in cattle. Brimer, L; Friis, C; Skaanild, MT, 2001) | 0.31 |
| "Pyrrolizidine alkaloids (PAs) are feeding deterrents and toxic compounds to generalist herbivores." | ( Toxicity of pyrrolizidine alkaloids to Spodoptera exigua using insect cell lines and injection bioassays. Klinkhamer, PG; Leiss, KA; Nuringtyas, TR; van Oers, MM; Verpoorte, R, 2014) | 0.4 |
| " Treatment with seneciphylline and senkirkine had adverse effects on the development and organic morphodifferentiation of embryos." | ( [Embryotoxicity of Senecionis Scandentis Hebra on in vitro cultured mouse embryos]. Cui, HY; Han, JY; Li, CY; Liang, AH; Lu, YT; Yi, Y; Zhang, YS; Zhao, Y, 2014) | 0.68 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "The main aim of the current study was to obtain forward dosimetry assessments of pyrrolizidine alkaloid senkirkine plasma and liver concentrations by setting up a human physiologically based pharmacokinetic (PBPK) model based on the limited information available." | ( Plasma Concentration Profiles for Hepatotoxic Pyrrolizidine Alkaloid Senkirkine in Humans Extrapolated from Rat Data Sets Using a Simplified Physiologically Based Pharmacokinetic Model. Kamiya, Y; Kato, A; Miura, T; Murayama, N; Shimizu, M; Yamazaki, H, 2022) | 1.17 |
| "Using a simplified PBPK model established using rat pharmacokinetic data, forward dosimetry was conducted." | ( Plasma Concentration Profiles for Hepatotoxic Pyrrolizidine Alkaloid Senkirkine in Humans Extrapolated from Rat Data Sets Using a Simplified Physiologically Based Pharmacokinetic Model. Kamiya, Y; Kato, A; Miura, T; Murayama, N; Shimizu, M; Yamazaki, H, 2022) | 0.96 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " We previously determined that four DNA adducts were formed in rats dosed with riddelliine." | ( Pyrrolizidine alkaloid-derived DNA adducts as a common biological biomarker of pyrrolizidine alkaloid-induced tumorigenicity. Cai, L; Doerge, DR; Fu, PP; Lin, G; Von Tungeln, LS; Xia, Q; Zhao, Y, 2013) | 0.39 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| macrolide | A macrocyclic lactone with a ring of twelve or more members derived from a polyketide. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID339034 | Cytotoxicity against human A204 cells after 24 hrs by soft agar colony forming assay | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (19)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (31.58) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 23.63
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.63) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 20 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||